SELLAS Life Sciences Group (SLS) News Today $1.74 +0.12 (+7.41%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.79 +0.05 (+2.87%) As of 04:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR ConferenceApril 28, 2025 | globenewswire.comSELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher - Time to Buy?SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 1.6% - Time to Buy?April 26, 2025 | marketbeat.comSELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.comSellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trialApril 9, 2025 | markets.businessinsider.comSELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AMLApril 8, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. Common Stock (SLS) Insider ActivityMarch 30, 2025 | nasdaq.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 21, 2025 | finanznachrichten.deSELLAS Life Sciences Group (NASDAQ:SLS) Issues Quarterly Earnings ResultsSELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) posted its earnings results on Thursday. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03.March 21, 2025 | marketbeat.comBrooklyn FI LLC Takes Position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)Brooklyn FI LLC bought a new position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 594,919 shares of the company's stockMarch 21, 2025 | marketbeat.comSELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 20, 2025 | globenewswire.comSELLAS Life Sciences Group (SLS) to Release Earnings on ThursdaySELLAS Life Sciences Group (NASDAQ:SLS) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Decrease in Short InterestSELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a significant decline in short interest in February. As of February 15th, there was short interest totalling 8,650,000 shares, a decline of 11.8% from the January 31st total of 9,810,000 shares. Based on an average daily volume of 2,700,000 shares, the days-to-cover ratio is currently 3.2 days.March 7, 2025 | marketbeat.comSellas reports Phase IIa trial data of SLS009 for DLBCL treatmentFebruary 21, 2025 | msn.comSELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLFebruary 20, 2025 | finanznachrichten.deSELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trialFebruary 20, 2025 | msn.comSellas Life Sciences’ zanubrutinib combination shows efficacy in DLBCLFebruary 20, 2025 | markets.businessinsider.comSELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLFebruary 20, 2025 | globenewswire.comInvestors Buy High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the target of unusually large options trading on Monday. Stock investors purchased 9,455 call options on the company. This represents an increase of 146% compared to the typical daily volume of 3,838 call options.February 4, 2025 | marketbeat.comSELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw some unusual options trading on Monday. Traders acquired 9,455 call options on the stock. This is an increase of approximately 146% compared to the average volume of 3,838 call options.February 3, 2025 | marketbeat.comSellas $25M registered direct offering priced at $1.27 per share and warrantJanuary 29, 2025 | markets.businessinsider.comSELLAS secures $25 million in registered direct offeringJanuary 28, 2025 | msn.comSELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 28, 2025 | globenewswire.comPositive Phase 3 Results and Investment Opportunity Highlighted in SELLAS Life Sciences GroupJanuary 25, 2025 | markets.businessinsider.comSellas Life Sciences announces IDMC completed interim analysis of REGAL trialJanuary 24, 2025 | markets.businessinsider.comSellas Says IDMC Recommends Continuation Of REGAL Trial Of GPS In Acute Myeloid LeukemiaJanuary 23, 2025 | markets.businessinsider.comSELLAS Life Sciences falls after data for blood cancer therapyJanuary 23, 2025 | msn.comSELLAS shares tumble on interim trial resultsJanuary 23, 2025 | msn.comSELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid LeukemiaJanuary 23, 2025 | globenewswire.comSELLAS Life Sciences amends executive severance agreementsJanuary 16, 2025 | msn.comSELLAS Life Sciences Amends Severance for Key ExecutivesJanuary 16, 2025 | tipranks.comSELLAS Life Sciences Group, Inc.: SELLAS Announces Key Business Objectives for 2025January 8, 2025 | finanznachrichten.deSELLAS Announces Key Business Objectives for 2025January 8, 2025 | globenewswire.comPromising Phase 2 Results and Strategic Potential Drive Buy Rating for SELLAS Life Sciences’ SLS009December 12, 2024 | markets.businessinsider.comSellas Life Sciences triggers interim analysis in Phase 3 REGAL trialDecember 10, 2024 | markets.businessinsider.comSellas Life Sciences reports OS, ORR data from Phase 2 trial of SLS009December 10, 2024 | markets.businessinsider.comSELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid LeukemiaDecember 10, 2024 | globenewswire.comSELLAS Stock Announces Positive Data From Phase 2 Trial Of SLS009December 9, 2024 | markets.businessinsider.comSELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AMLDecember 9, 2024 | globenewswire.com793,835 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Purchased by Anson Funds Management LPAnson Funds Management LP purchased a new position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 793,835 shares of the company's stock, valDecember 8, 2024 | marketbeat.comSellas Announces Positive Data From Preclinical Studies Of SLS009November 27, 2024 | markets.businessinsider.comSELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid CancersNovember 27, 2024 | globenewswire.comPromising Clinical Trials and Strong Financial Position Bolster Buy Rating for SELLAS Life Sciences GroupNovember 16, 2024 | markets.businessinsider.comWe're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn RateNovember 16, 2024 | finance.yahoo.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 14, 2024 | finanznachrichten.deSELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | globenewswire.comSellas Life Sciences options imply 22.6% move in share price post-earningsNovember 12, 2024 | markets.businessinsider.comSELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024November 5, 2024 | globenewswire.comSELLAS' Galinpepimut-S Gets Rare Pediatric Disease Designation For Treatment Of Pediatric AMLOctober 15, 2024 | markets.businessinsider.comSELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid LeukemiaOctober 15, 2024 | globenewswire.comMubadala’s Kelix bio acquires GHH’s pharma assets to expand its life sciences portfolioOctober 14, 2024 | msn.com Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address SLS Media Mentions By Week SLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLS News Sentiment▼1.180.73▲Average Medical News Sentiment SLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLS Articles This Week▼11▲SLS Articles Average Week Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Maravai LifeSciences News Verve Therapeutics News GH Research News Mind Medicine (MindMed) News Sage Therapeutics News Upstream Bio News Ginkgo Bioworks News ABIVAX Société Anonyme News REGENXBIO News Precigen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLS) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLS Stock Free SLS Stock Alerts